Canada's Fight Against Brain Cancer's Silent Crisis

TORONTO, ON – April 21, 2026 – This May, as iconic landmarks across Canada illuminate the night sky in grey, they will cast a light on a stark and often overlooked reality: the urgent crisis of brain cancer. Spearheading the charge is Brain Cancer Canada (BCC), a unique national charity launching a sweeping Brain Cancer Awareness Month campaign that combines national visibility with critical new investments in research, all aimed at confronting a disease that remains one of oncology’s most formidable challenges.

The initiative will see a series of community events, educational campaigns, and inspiring stories culminate in the annual Gala for Brain Cancer Research. But behind the public-facing events lies a desperate need for progress against a disease that continues to devastate thousands of Canadian families each year.

“But Brain Cancer Awareness Month is about more than recognition, it’s about action,” said Angela Scalisi, Chair of Brain Cancer Canada. “Through national visibility, community support and critical research funding, we are working to change the future for patients and families facing this devastating diagnosis.”

The Grim Reality of a Devastating Disease

The statistics surrounding brain cancer in Canada paint a sobering picture. Every day, an average of nine Canadians are diagnosed with brain cancer. It stands as the leading cause of cancer-related death for children and young adults under the age of 40, cruelly cutting short lives that have barely begun. The five-year net survival rate for brain tumours hovers at a bleak 19%, a figure that has seen tragically little improvement in decades.

At the heart of this challenge is glioblastoma, the most common and aggressive malignant brain tumour in adults. For those diagnosed, the prognosis is often measured in months, not years. Canadian data from 2010 to 2017 revealed a median survival time of just 8.1 months, with only 4.9% of patients surviving five years. Even with the current standard of care—a grueling regimen of surgery, radiation, and chemotherapy—median survival extends to roughly 14.6 months. The disease's lethality is compounded by the brain's inherent vulnerability; its limited capacity for self-repair and the protective blood-brain barrier, which thwarts many drug therapies, make treatment exceptionally difficult.

Patients can face a cascade of debilitating symptoms, from severe headaches and seizures to progressive memory loss and profound personality changes, depending entirely on the tumour's location. This complexity underscores the desperate need for novel research and innovative therapeutic strategies.

A Volunteer Vanguard Maximizing Impact

Confronting this challenge is Brain Cancer Canada, an organization distinguished by its remarkable operational model. As the country's only national charity dedicated exclusively to funding brain cancer research, it is run entirely by volunteers. This 100% volunteer-driven structure ensures that every single dollar raised is channeled directly into scientific discovery, maximizing the impact of each donation.

Since its founding in 2015, the organization has directed nearly $3 million toward 31 distinct research projects at over a dozen institutions. This focused funding has earned BCC recognition from leading neurospecialists as a foremost mechanism for advancing brain cancer research in Canada. The organization's mission is deeply personal, born from the experience of its founder, Angela Scalisi, whose brother Bernardo fought the disease with courage for 12 years before passing away in 2025 at the age of 37. This personal connection fuels the organization's unwavering commitment to transforming a journey of loss into one of purpose and hope for others.

As part of its May campaign, BCC is announcing a new wave of funding for projects targeting the most aggressive forms of the disease, building on a portfolio that already includes grants for pediatric brain tumours, glioblastoma, and immunotherapies.

From Public Awareness to Scientific Breakthroughs

This May, Brain Cancer Canada is masterfully bridging the gap between public awareness and the intricate world of scientific research. The nationwide landmark lightings serve as a powerful, visible tribute to the brain cancer community and a stark reminder of the disease’s underfunded status. This public engagement is designed to fuel the engine of discovery, most notably through the annual Gala for Brain Cancer Research.

Scheduled for May 22 at the Paramount Event Space in Vaughan, Ontario, the gala is the most impactful fundraising event for brain cancer research in Canada. The evening will be hosted by Catherine Wreford, a celebrated performer and winner of The Amazing Race Canada. Wreford is more than a host; she is a powerful symbol of resilience. Diagnosed in 2013 with an incurable anaplastic astrocytoma and given a prognosis of two to six years, she has defied expectations for over a decade, using her platform to advocate for research and inspire hope.

The gala's keynote address will be delivered by Dr. Cynthia Hawkins, a world-renowned neuropathologist from The Hospital for Sick Children (SickKids) in Toronto. Dr. Hawkins is at the forefront of research into deadly pediatric brain tumours like Diffuse Intrinsic Pontine Glioma (DIPG). Her work, which includes defining the genetic and epigenetic landscape of these tumours, aims to develop effective treatments for the youngest patients. Her presence at the gala highlights the direct line between fundraising and the high-impact science it enables; in late 2024, Brain Cancer Canada awarded Dr. Hawkins and her collaborators $100,000 to advance their critical research into DIPG/DMG.

Funding the Future of Treatment

The funds raised by Brain Cancer Canada are not abstract investments; they are targeted injections of capital into the most promising areas of research. The organization’s recent grant portfolio reveals a strategic focus on innovation, supporting projects with the potential to transform treatment paradigms. Recent awards include an $85,000 grant for researching recurrent glioblastoma, a $100,000 grant for advancing gene therapy for a specific pediatric brain cancer, and an $80,000 grant for developing dual-function therapies that harness the body’s own immune system to fight glioblastomas.

This funding has already yielded tangible results. Research co-led by the Singh Lab at McMaster University, supported by Brain Cancer Canada, recently uncovered a previously unknown migration pathway that cancer cells use to infiltrate the brain. This discovery has opened new therapeutic avenues for glioblastoma. Further work from the same lab identified how certain brain cells can inadvertently promote tumour growth and, crucially, pointed to an existing drug that could potentially disrupt this mechanism.

By funding bold, early-stage projects and supporting the nation’s top scientific minds, the volunteer-led organization is systematically dismantling the barriers to progress. Each illuminated landmark and every dollar raised at the upcoming gala represents another step forward in the relentless pursuit of a future where a brain cancer diagnosis is no longer a death sentence.